Clinical trials: Reflux Esophagitis (RE)
Gastric Ulcer (GU), Duodenal Ulcer (DU)
A Phase I/III Study of D961H 10 mg and 20 mg in Japanese Paediatric Patients With Gastrointestinal Acid Related Diseases
The objective of this study is to assess the safety, pharmacokinetics, pharmacodynamics and efficacy of repeated once daily oral administration of D961H 10 mg and D961H 20 mg in Japanese paediatric patients aged 1 to 14 years old…
- Conditions
- Gastric Ulcer (GU), Duodenal Ulcer (DU), Anastomotic Ulcer (AU), Non-erosive Reflux Esophagitis Disease (NERD)
- Trial name
- NCT02153398
- Testing
- D961H sachet 10 mg, D961H capsule 10mg, D961H capsule 20 mg
- Where
- 15 sites in Japan
- Volunteers
- 55 people
- Sponsor
- AstraZeneca
Repeatedly Recurring Esophagitis, Relapsing Reflux Esophagitis
Nexium Capsules RE Maintenance Specific Clinical Experience Investigation
The purpose of this study is to collect following data in patients given Nexium capsule (Nexium) in usual post-marketing use as the maintenance therapy for repeatedly recurring/relapsing reflux oesophagitis.
- Trial name
- NCT01562639
- Where
- 46 sites in Japan
- Volunteers
- 647 people
- Sponsor
- AstraZeneca
Reflux Esophagitis (RE), Non-erosive Reflux Disease (NERD)
Analysis of GERD Symptoms Using Gastroesophageal Reflux Impact Score Questionnaire for Quality of Life
Even the patients complain GERD symptoms such as heartburn and acid regurgitation the final diagnosis could be reflux esophagitis (RE), non-erosive reflux disease (NERD) and even functional heartburn (FH).
- Conditions
- Reflux Esophagitis (RE), Non-erosive Reflux Disease (NERD), Functional Heartburn (FH)
- Trial name
- NCT01536080
- Where
- South Korea
- Volunteers
- 207 people
- Sponsor
- Seoul National University Bundang Hospital
Reflux Esophagitis
Nexium Capsules S-CEI for Justification of Esomeprazole in Acid Related Disease for Reflux Symptom Healing Based on Patient Clinical Outcomes
The objective of this investigation is to collect following data in patients given NEXIUM capsule (NEXIUM) in usual post-marketing use.
- Trial name
- NCT02477475
- Where
- 47 sites in Japan
- Volunteers
- 1,595 people
- Sponsor
- AstraZeneca